AbbVie's fiscal second quarter arrived three years removed from the loss of exclusivity on Humira, once the world's best-selling drug, and the company is now compounding off the replacement platform with a speed most big-pharma names have lost. The quarter set the story plainly: net revenues rose 10% to $16.99 billion, immunology grew 15%, neuroscience grew 20%, and adjusted earnings per share rose nearly 23% to $3.65 (up from a comparable $2.97). The accounting earnings line, $2.03 on a GAAP basis, is the wrong number to read - it is dragged down by more than a billion dollars a year in acquired in-process R&D and milestone charges plus swings in the fair value of acquisition contingent consideration, items management strips out because they are one-off and non-cash. The adjusted number is the operating one, and it is compounding.
The central question is no longer whether AbbVie replaced Humira - it has. It is whether the stock's premium is sustainable now that the replacement is proven. At roughly 18x forward adjusted earnings, AbbVie trades above most of large-cap pharma, a valuation built on the momentum of Skyrizi and Rinvoq and the neuroscience franchise. That premium is the report's question, not yet its verdict. The answer turns on whether the growth platform keeps compounding, whether the flat Aesthetics business stops being a drag, and whether the roughly $10.9 billion acquisition of Apogee Therapeutics - announced in June, expected to close in the third quarter - lands as the bridge to the franchise's next leg rather than a premium-priced gamble on atopic dermatitis and asthma.
Management sees the setup as durable. The company raised its quarterly dividend to $1.73, repurchased $1.1 billion of its own shares in the first half, and is spending $10.9 billion in cash to deepen immunology - capital-allocation behavior that only makes sense if it believes the growth era is real. The dividend yields about 2.8%. What makes this quarter consequential is not the earnings beat but the fact that AbbVie is now being run, and priced, as a growth company whose biggest test is sustaining the multiple rather than surviving it.